The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease
Open Access
- 15 October 2013
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 14 (10), 20597-20613
- https://doi.org/10.3390/ijms141020597
Abstract
The epidermal growth factor receptor (EGFR) family and its ligands serve as a switchboard for the regulation of multiple cellular processes. While it is clear that EGFR activity is essential for normal cardiac development, its function in the vasculature and its role in cardiovascular disease are only beginning to be elucidated. In the blood vessel, endothelial cells and smooth muscle cells are both a source and a target of EGF-like ligands. Activation of EGFR has been implicated in blood pressure regulation, endothelial dysfunction, neointimal hyperplasia, atherogenesis, and cardiac remodeling. Furthermore, increased circulating EGF-like ligands may mediate accelerated vascular disease associated with chronic inflammation. Although EGFR inhibitors are currently being used clinically for the treatment of cancer, additional studies are necessary to determine whether abrogation of EGFR signaling is a potential strategy for the treatment of cardiovascular disease.This publication has 101 references indexed in Scilit:
- Heart to heart with trastuzumab: a review on cardiac toxicityTargeted Oncology, 2011
- Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migrationCardiovascular Research, 2011
- Caveolin-1 negatively regulates a metalloprotease-dependent epidermal growth factor receptor transactivation by angiotensin IIJournal of Molecular and Cellular Cardiology, 2011
- Mechanisms of myogenic tone of coronary arteriole: Role of down stream signaling of the EGFR tyrosine kinaseMicrovascular Research, 2011
- Periadventitial delivery of anti‐EGF receptor antibody inhibits neointimal macrophage accumulation after angioplasty in a hypercholesterolaemic rabbitInternational Journal of Experimental Pathology, 2010
- Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type II diabetic miceLaboratory Investigation, 2010
- A Differential Role for Endocytosis in Receptor-Mediated Activation of Nox1Antioxidants and Redox Signaling, 2010
- Diabetes and microvascular pathophysiology: role of epidermal growth factor receptor tyrosine kinaseDiabetes/Metabolism Research and Reviews, 2009
- Heparin-binding EGF-like growth factor is a potent dilator of terminal mesenteric arteriolesMicrovascular Research, 2009
- Role of the Sec61 Translocon in EGF Receptor Trafficking to the Nucleus and Gene ExpressionMolecular Biology of the Cell, 2007